Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III maintenance study of TQB2450 + anlotinib after chemoradiotherapy in limited-stage small cell lung cancer
CTR20242082Phase 3Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Jul 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart, anlotinib in small cell lung cancer (SCLC), sponsored by Nanjing Shunxin Pharmaceutical. Started Jul 2024; status: active.
02
Drugs
benmelstobartanlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20242082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242082.